First Patients Recruited and Enrolled in Cellceutix Clinical

First Patients Recruited and Enrolled in Cellceutix Clinical Trial of
Novel Anti-Cancer Drug Kevetrin 
Elsevier Business Intelligence Reports Cellceutix "Developing a
Still-Secret Prodrug For Psoriasis" and a "Heralded Cancer Candidate" 
BEVERLY, MA -- (Marketwire) -- 10/29/12 --  Cellceutix Corporation
(OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical
company focused on discovering small molecule drugs to treat unmet
medical conditions, including drug-resistant cancers and autoimmune
diseases, is pleased to report that the first patients have been
recruited and enrolled for the clinical trials of Kevetrin(TM), the
Company's novel cancer drug in development. The clinical trials are
being conducted on patients with advanced solid tumors at Harvard
University's Dana-Farber Cancer Institute and partner Beth Israel
Deaconess Medical Center. 
Based on dialogue with the clinical sites, the Company anticipates
updating shareholders next week that dosing of the first patient has
been administered. 
"We are extremely pleased to hear that the first patients will begin
therapy with Kevetrin(TM) in a matter of days," said Dr. Krishna
Menon, Chief Scientific Officer at Cellceutix. "Not only is this is a
substantial milestone for Cellceutix and its shareholders, but 
feel it is important to the field of oncology. As a novel compound
that directly impacts p53, the "Guardian Angel of the Human Genome,"
we look forward to a steady patient enrollment and future outcomes
that potentially could change the landscape of cancer therapeutics. 
Elsevier Business Intelligence 
Cellceutix announced that Elsevier Business Intelligence has released
a profile article on the Company for its latest edition of its
publication "Start Up: Emerging Medical Ventures."  
Elsevier, a division of Reed Elsevier Group PLC, is the world's
leading provider of science and health information, serving more than
30 million scientists, students and health and information
professionals worldwide. 
In the article, Elsevier's Deborah Erickson discusses the uniqueness
of the Company's Prurisol(TM) as a new therapeutic candidate for
psoriasis, and the clinical trials at Dana-Farber Cancer Center and
Beth Israel Deaconess on Kevetrin(TM) as a novel, p53-activating
anti-cancer drug. Regularly referencing Cellceutix as "anything but a
normal start-up," the write-up provides a succinct overview of the
Company, its "all-star" advisory staff and offers insight into
Kevetrin and Prurisol. 
Shareholders and interested parties are encouraged to view the
article at: 
"We are very pleased to have been approached by Elsevier. They have a
tremendous global outreach and the additional exposure is positive
for our company," commented Leo Ehrlich, Chief Executive Officer at
Cellceutix. "I found it particularly interesting how attracted they
were to Prurisol and the incredible potential that they see for the
drug. Because of the p53 connection and strong possibilities for
Kevetrin(TM), many people overlook how impactful and valuable
Prurisol can be as well." 
About Kevetrin(TM) 
As a completely new class of chemistry in medicine, Kevetrin(TM) has
significant potential to be a major breakthrough in the treatment of
solid tumors. Mechanism of action studies showed Kevetrin's unique
ability to affect both wild and mutant types of p53 (often referred
to as the "Guardian Angel Gene" or the "Guardian Angel of the Human
Genome") and that Kevetrin strongly induced apoptosis (cell death),
characterized by activation of Caspase 3 and cleavage of PARP.
Activation of p53 also induced apoptosis by inducing the expression
of p53 target gene PUMA. p53 is an important tumor suppressor that
acts to restrict proliferation by inducing cell cycle checkpoints,
apoptosis, or cellular senescence. 
In more than 50 percent of all human carcinomas, p53 is limited in
its anti-tumor activities by mutations in the protein itself.
Currently, there are greater than 10 million people with tumors that
contain inactivated p53, while a similar number have tumors in which
the p53 pathway is partially abrogated by inactivation of other
signaling components. This has left cancer researchers with the grand
challenge of searching for therapies that could restore the protein's
protective function, which Kevetrin appears to be doing the majority
of the time. 
The clinical trial titled, "A Phase 1, Open-Label, Dose-Escalation,
Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin
(Thioureidobutyronitrile) Administered Intravenously, in Patients
With Advanced Solid Tumors," is available at: 
About Prurisol 
Prurisol is a small molecule, acting on the principles of immune
modulation and PRINS reduction that has been found to be effective
against psoriasis in animal models, both in induced psoriasis as well
as a xenograft model with human psoriatic tissue. It is 25% orally
bioavailable allowing the potential for oral administration. Prurisol
was studied in SCID mice that were irradiated then engrafted with
human ps
oriatic tissue by inserting human psoriatic tissue under the
skin using a trocar. The results of the research showed that Prurisol
significantly reduced all psoriatic endpoints measured relative to
controls. More detailed information and images of the animal models
can be found at:  
About Elsevier 
Elsevier is a world-leading provider of scientific, technical and
medical information products and services. The company works in
partnership with the global science and health communities to publish
more than 2,000 journals, including The Lancet and Cell, and close to
20,000 book titles, including major reference works from Mosby and
Saunders. Elsevier's online solutions include ScienceDirect, Scopus,
Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the
productivity of science and health professionals, and the SciVal
suite and MEDai's Pinpoint Review, which help research and health
care institutions deliver better outcomes more cost-effectively. 
A global business headquartered in Amsterdam, Elsevier employs 7,000
people worldwide. The company is part of Reed Elsevier Group PLC, a
world-leading publisher and information provider, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange). 
About Cellceutix 
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly
traded company under the symbol "CTIX". It is an emerging
bio-pharmaceutical company focused on the development of its pipeline
of compounds targeting areas of unmet medical need. Our flagship
compound, Kevetrin(TM), is an anti-cancer drug which has demonstrated
the ability in pre-clinical studies to regulate the p53 pathway and
attack cancers which have proven resistant to today's cancer
therapies (drug-resistant cancers). Cellceutix also owns the rights
to seven other drug compounds, including KM-133, which is in
development for psoriasis, and KM-391 for the treatment of the core
symptoms of autism. More information is available on the Cellceutix
web site at 
Safe Harbor Forward-Looking Statements
 To the extent that statements
in this press release are not strictly historical, including
statements as to revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
financial conditions, future collaboration agreements, the success of
the Company's development, events conditioned on stockholder or other
approval, or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to
differ materially from the statements made. Factors that may impact
Cellceutix's success are more fully disclosed in Cellceutix's most
recent public filings with the U.S. Securities and Exchange
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717 
Press spacebar to pause and continue. Press esc to stop.